SLC5A2 and heart failure: Sodium–glucose co-transporter 2 (SGLT2) inhibitors, that initially emerged as a new diabetic treatment, succeeded to establish their role as one of the four pillars for the management of heart failure with reduced ejection fraction (HFrEF)13.